Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity

Kabil, Mohamed Fawzi; Mahmoud, Mohamed Y.; Bakr, Alaa F.; Zaafar, Dalia; El‐Sherbiny, Ibrahim M.

doi:10.1016/j.lfs.2022.120731

Cited by 10 publications

(5 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A higher oxidative stress state was reported to increase DNA damage and chromosomal aberrations and promote disease progression. This finding was consistent a recent study which demonstrated that cancer cell proliferation and survival were promoted through ROS-activated pathways (Kabil et al, 2022). Additionally, a clinical trial showed that elevated MDA and ROS levels in patients treated with tyrosine kinases could indicate resistance to the treatment (Petrola et al, 2012).…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

The Role of Pioglitazone Against Ehrlich Solid Carcinoma Mice Model Through Antiproliferative and Antiangiogenic Pathways

Zaafar¹,

Khalil²,

Hassanin³

et al. 2023

AAVS

View full text Add to dashboard Cite

C ancer is the second prominent cause of death globally, also prevalence is expected to increase by 2040 due to the increase in the new cases of malignancy annually (Bray et al., 2018). Chemotherapeutic medications are extensively used in cancer treatment either alone or with radiotherapy and surgical interventions. Cisplatin, one of the antineoplastic alkylating agents, has a significant proven efficacy against many types of malignancies, such as the neck, ovaries, testes, and lung cancers (Al-Eitan et al., 2020). However, despite its substantial antineoplastic

show abstract

Section: Discussionsupporting

confidence: 91%

“…In this study, Cyclin D1 expression was accompanied by a more favorable outcome in the Cis+ (Pio HD)-treated group than the untreated control and pioglitazone-treated groups. Overexpression of Cyclin D1 is investigated in many cancers related to progression and metastasis (Kabil et al, 2022).…”

Section: Advances In Animal and Veterinary Sciencesmentioning

confidence: 99%

The Role of Pioglitazone Against Ehrlich Solid Carcinoma Mice Model Through Antiproliferative and Antiangiogenic Pathways

Zaafar¹,

Khalil²,

Hassanin³

et al. 2023

AAVS

View full text Add to dashboard Cite

show abstract

“…Subsequently, the slides were stained with hematoxylin and eosin (H&E) and observed using Olympus BX43 light microscope linked with a digital camera (DP27) and CellSens dimensions software. The histological damage score was assessed at 200×, as previously described [48].…”

Section: Histopathological and Immunohistopathological Assessmentmentioning

confidence: 99%

Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency

et al. 2022

Self Cite

View full text Add to dashboard Cite

Breast cancer is a prevalent tumor and causes deadly metastatic complications. Myriad cancer types, including breast cancer, are effectively treated by methotrexate (MTX). However, MTX hydrophobicity, adverse effects and the development of resistance have inspired a search for new effective strategies to overcome these challenges. These may include the addition of a bioenhancer and/or encapsulation into appropriate nano-based carriers. In the present study, the anticancer effect of MTX was fortified through dual approaches. First, the concomitant use of piperine (PIP) as a bioenhancer with MTX, which was investigated in the MCF-7 cell line. The results depicted significantly lower IC50 values for the combination (PIP/MTX) than for MTX. Second, PIP and MTX were individually nanoformulated into F-127 pluronic nanomicelles (PIP-NMs) and F-127/P-105 mixed pluronic nanomicelles (MTX-MNMs), respectively, validated by several characterization techniques, and the re-investigated cytotoxicity of PIP-NMs and MTX-MNMs was fortified. Besides, the PIP-NMs/MTX-MNMs demonstrated further cytotoxicity enhancement. The PIP-NMs/MTX-MNMs combination was analyzed by flow cytometry to understand the cell death mechanism. Moreover, the in vivo assessment of PIP-NMs/MTX-MNMs was adopted through the Ehrlich ascites model, which revealed a significant reduction of the tumor weight. However, some results of the tumor markers showed that the addition of PIP-NMs to MTX-MNMs did not significantly enhance the antitumor effect.

show abstract

“…Subsequently, the tissues were stained with hematoxylin and eosin (H&E) and observed under a light microscope (Nikon, Tokyo, Japan) with a digital camera attached to assess the damage on the tissues. 37 …”

Section: Methodsmentioning

confidence: 99%

Design and Application of pH-Responsive Liposomes for Site-Specific Delivery of Cytotoxin from Cobra Venom

Lin,

Jing,

Yan

et al. 2024

IJN

View full text Add to dashboard Cite

Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity

Cited by 10 publications

References 66 publications

The Role of Pioglitazone Against Ehrlich Solid Carcinoma Mice Model Through Antiproliferative and Antiangiogenic Pathways

The Role of Pioglitazone Against Ehrlich Solid Carcinoma Mice Model Through Antiproliferative and Antiangiogenic Pathways

Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency

Design and Application of pH-Responsive Liposomes for Site-Specific Delivery of Cytotoxin from Cobra Venom

Contact Info

Product

Resources

About